Abstract Purpose: Epidemiologic studies have shown that reduced levels of vitamin D represent a major risk factor for prostate cancer. In this report, we have examined the efficacy of 1a, 25-dihydroxyvitamin D 3 (1,25 D 3 ) as a chemopreventive agent using Nkx3.1; Pten mutant mice, which recapitulate stages of prostate carcinogenesis from prostate intraepithelial neoplasia (PIN) to adenocarcinoma. Experimental Design: 1,25 D 3 (or vehicle) was delivered continuously to Nkx3.1; Pten mutant or control mice for a 4-month period beginning before (precancerous cohort) or after (cancerous cohort) these mice developed PIN. At the conclusion of the study, the mice were analyzed for the occurrence of PIN and/or cancer phenotypes by histologic analyses and immunostaining using known markers of cancer progression in these mice. Results: We found that sustained delivery of 1,25 D 3 to the Nkx3.1; Pten mutant mice resulted in a significant reduction in the formation of PIN while having no apparent effect on the control mice. Furthermore, 1,25 D 3 was maximally effective when delivered before, rather than subsequent to, the initial occurrence of PIN. We further show that this 1,25 D 3^m ediated inhibition of PIN was coincident with up-regulation of vitamin D receptor expression in the prostatic epithelium of the mutant mice, as well as in CASP prostate epithelial cell lines developed from these mice, while having no effect on androgen receptor expression or androgen receptor signaling. Conclusion: Our findings show the value of chemoprevention studies using Nkx3
potential efficacy of vitamin D as a chemopreventive agent for prostate cancer has attracted considerable interest because a large body of epidemiologic, cell culture, and clinical studies have suggested its antitumor activities for prostate cancer (e.g., refs. 7 -14) . However, unlike colon cancer for which the benefits of vitamin D in chemoprevention have been well established (reviewed in ref. 15 ), many critical issues remain unresolved about the effectiveness of vitamin D for prostate cancer prevention, despite numerous studies in animal models and human clinical trials that have been primarily designed to assess its effects in advanced prostate cancer (13, 16 -19) .
In the current study, we have examined the efficacy of 1a,25-dihydroxyvitamin D 3 (1,25 D 3 ) for prevention of prostate cancer using a mouse model based on the combinatorial lossof-function of the Nkx3.1 homeobox and Pten tumor suppressor genes (20, 21) , which are known to be relevant for human prostate cancer (22, 23) . Among their advantages for chemoprevention studies, Nkx3.1; Pten mutant mice recapitulate many aspects of human prostate cancer, including its critical dependence on aging for cancer progression (20, 21) . Moreover, because they represent an autochthonous (indigenous) model of prostate cancer, Nkx3.1; Pten mutant mice enable the evaluation of 1,25 D 3 , or other potential chemopreventive agents in the context of the prostate microenvironment and an intact host immune system, which are likely to have a significant effect on the efficacy of such agents in vivo (24) .
We now report that 1,25 D 3 results in a significant reduction in the incidence and severity of the prostate intraepithelial neoplasia (PIN) phenotypes when delivered to Nkx3.1; Pten mutant mice before, but not subsequent to, the occurrence of PIN. We further show that the chemopreventive effects of 1,25 D 3 were coincident with increased expression of vitamin D receptor in the prostatic epithelium of these mutant mice and their derivative cell lines. Our studies show the value of the Nkx3.1; Pten mouse model for chemoprevention studies and provide new insights about the design of clinical trials to assess the role of vitamin D for chemoprevention of prostate cancer.
Materials and Methods
Mutant mice and analyses. The Nkx3.1; Pten mutant mice have previously been described (20, 21 25 D 3 ; to confirm that the compound was active during the duration of the experiment, calcium levels were measured from serum by a colorimetric method with a Calcium Reagent Set (Teco Diagnostics, Anaheim, CA). Aside from the delivery of 1,25 D 3 , all other variables, such as diet and environmental factors, were maintained under controlled conditions for the duration of the experiment.
At the time of sacrifice, the prostatic lobes were dissected individually, visually inspected, and fixed in formalin for histopathologic analyses. Histologic analyses was done on paraffin-embedded tissues by H&E staining as described (20, 21) . Criteria for grading PIN phenotypes in Nkx3.1; Pten mutant mice, and specifically for distinguishing low-grade versus high-grade PIN, are well established and have previously been described in detail (25) . Immunohistochemistry was done as described (21) Evaluation of the phenotype. To evaluate the consequences of 1,25 D 3 treatment, the experimental (mutant and wild-type) mice were examined to assess their histologic phenotype and to evaluate the status of markers of cancer progression by immunohistochemical staining. In particular, for each experimental mouse, multiple H&E-stained sections from at least six distinct regions of the anterior and dorsolateral prostatic lobes were evaluated for the occurrence of PIN; the slides were evaluated blinded and independently by three of us (H.G., W.B-P., and C.A.S). Data are shown for the anterior lobe; similar results were obtained for the dorsolateral prostate (data not shown). To further verify the phenotypic assessment, immunohistochemical analyses was done on sections from the anterior prostate of eight independent mice per experimental group using known markers of cancer progression in these mutant mice (i.e., actin, which is attenuated, and phospho-Akt, which is up-regulated during cancer progression; refs. 20, 21) . Thus, the histologic grading for each experimental animal presented in Table 1 represents the sum of the histologic grading (done by three of us independently) plus the immunohistochemical staining for actin and Akt. Cell culture studies. The CASP cell lines, which were generated from Nkx3.1; Pten mutant mice, have characteristics of prostate epithelial cells, were derived from primary tumors, retain wild-type androgen receptor, and express androgen receptor at levels that are comparable to those expressed in the endogenous prostate epithelium (26, 27) . We used one CASP cell line that is dependent on androgens for growth in culture (CASP 2-1) and its companion cell line (CASP 1-1), which has similar growth and tumorigenic properties but is not androgen responsive (27) . CASP cells were grown in the presence of 1,25 D 3 or vehicle at a concentration of 1 Â 10 7 or 1 Â 10 9 . Media contained 1% charcoal/dextran -treated fetal bovine serum with or without dihydrotestosterone as indicated. Proliferation assays were done as described (28) Specifically, by 4 months of age, these mice develop focal lowgrade PIN, which, by 6 months of age, progresses to high-grade PIN. As these mice approach 9 months of age, the high-grade PIN lesions are extensive and completely encompass the prostatic lobe; by 12 months, these mice display regions of overt adenocarcinoma, as well as extensive high-grade PIN. In this study, we refer to Nkx3.1; Pten mutant mice younger than 6 months as the ''precancerous'' cohort and those older than 6 months as the ''cancerous'' cohort.
To Table 1 ). In initial studies, we determined that delivery of 23 or 46 ng/kg/d was effective for inhibiting the PIN/cancer phenotypes in these mice; 5 we used the latter dosage for subsequent studies. To ensure delivery of a constant amount of 1,25 D 3 for the duration of the experiment (up to 4 months), we used osmotic pumps containing vehicle or 1,25 D 3 . The pumps were implanted into the back of the experimental mice and replaced monthly. Notably, we confirmed that the levels of calcium in the serum of 1,25 D 3 -treated mice were much higher than those in the control mice at the conclusion of the experiment.
1,25 D 3 inhibits PIN in precancerous but not cancerous mutant mice. Using this experimental paradigm, we found that sustained delivery of 1,25 D 3 to the precancerous cohort of Nkx3.1; Pten mutant mice resulted in a significant inhibition (P < 0.001) in the occurrence of high-grade PIN, whereas it had no obvious effects on the histologic phenotype of the wild-type 5 W. Banach-Petrosky and C. Abate-Shen, unpublished data. Fig. 1B-I) . Specifically, at the conclusion of the 4-month study, the prostatic epithelium of these 1,25 D 3 -treated mutant mice (ages 8-9 months) contained large regions of relatively normal epithelium (Fig. 1H) . Moreover, even when PIN lesions occurred in these mice, they were typically small and focal (Fig. 1I) , similar to the characteristic phenotype of young (<6 months) Nkx3.1; Pten mutants (21, 25) . This phenotype contrasts strikingly with that of the age-matched vehicle-treated mutants, which display extensive high-grade PIN lesions that typically fill the lumen of the prostate (Fig. 1F  and G) , as is characteristic of these mutant mice by 8 to 9 months of age (20, 21) .
In marked contrast to its profound effects on the precancerous cohort, 1,25 D 3 was minimally effective for inhibiting prostate cancer progression when delivered to the cancerous cohort ( Fig. 1J-M ; Table 1 ). In particular, this group of Nkx3.1; Pten mutant mice displayed high-grade PIN lesions regardless of whether they received 1,25 D 3 or vehicle (Fig. 1J-M) . Moreover, 1,25 D 3 also had no effect on the histologic phenotypes of the age-matched wild-type mice (data not shown). These findings suggest that vitamin D may be effective for preventing or delaying the initial occurrence of prostate cancer, but less so for inhibiting its progression.
The decreased formation of PIN following delivery of 1,25 D 3 to the precancerous, but not the cancerous, cohort of mutant mice was further evident by inspection of histologic markers of prostate cancer progression (Fig. 2) . In particular, one characteristic feature of cancer progression in the Nkx3.1; Pten mutant mice is a marked attenuation of the stroma, which is evident by staining for smooth muscle actin (20, 21) . However, in the precancerous cohort, the stromal layer of 1,25 D 3 -treated mutant mice was largely intact and more similar to that of the wild-type prostate than to the attenuated stroma of the vehicle-treated mutants (N = 8 per group; Fig. 2A , G, M, and S). In contrast, in the cancerous cohort, the stroma was attenuated in both the vehicle-and 1,25 D 3 -treated groups (N = 8 per group; Fig. 2Y and E ¶) .
Another characteristic marker of cancer progression in Nkx3.1; Pten mutant mice is activation of the Akt kinase, which is a consequence of Pten loss-of-function (20, 21) . Notably, the precancerous cohort of 1,25 D 3 -treated mutant mice displayed minimal activation of Akt, in contrast to their vehicle-treated counterparts, which displayed robust levels of activated Akt (N = 8 per group; Fig. 2N and T) . In the cancerous group, however, the levels of Akt activation were similar for both the vehicle-and 1,25 D 3 -treated groups (N = 8 per group; Fig. 2Z and F ¶) . Taken together, these findings further suggest that 1,25 D 3 may be beneficial for inhibiting cancer initiation, although it may not be as effective for inhibiting cancer progression if initiation had already occurred.
1,25 D 3 promotes apoptosis in vivo in the context of the prostate microenvironment, whereas it inhibits cellular proliferation in culture. Interestingly, the 1,25 D 3 -treated mutant mice did not display a significant reduction in cellular proliferation, as evidenced by staining for Ki67 (N = 8; To reconcile this apparent discrepancy, we examined the consequences of 1,25 D 3 for growth in culture using CASP cells, which were derived from the Nkx3.1; Pten mutant mice (refs. 26, 27; Fig. 3A) . Notably, the CASP cells were derived from primary tumors, rather than metastases, and they retain wildtype androgen receptor function and, in general, are less highly transformed than most of the human prostate cancer cell lines, including LNCaP (26, 27) . 6 For these studies, we used two CASP cell lines, one that is androgen responsive (CASP 2-1) and one that is androgen nonresponsive, and we tested the consequences of 1,25 D 3 in these cell lines in the presence or absence of dihydrotestosterone. We found that 1,25 D 3 inhibited the growth of both CASP cell lines (CASP 2-1 and CASP 1-1) to a similar extent regardless of whether cells were grown in the presence or absence of dihydrotestosterone (Fig. 3A) . These findings show that 1,25 D 3 inhibits the growth of prostate epithelial cells in culture more significantly than in vivo, analogous to our previous study in which we observed a differential response of these cells to androgen ablation in culture versus in vivo (27) . Importantly, these studies suggest that the actions of chemopreventive agents may differ depending on the context in which they are tested, and emphasize the significance of the evaluating such agents in the context of the prostate microenvironment in vivo. 
Discussion
Whereas prevention is undoubtedly the most effective means of eradicating prostate cancer, there are many inherent challenges to investigating potential chemopreventive agents in the human population. Chemoprevention studies in mouse models can help to overcome these challenges and guide studies in humans (24) . Our current analyses in Nkx3.1; Pten mice, as well as previous reports using the TRAMP model of prostate cancer (32, 33) , emphasize the importance of investigating chemopreventive agents in autochthonous models, which enable investigations in the context of the prostate microenvironment.
Our current findings provide new insights about the use of vitamin D for chemoprevention of prostate cancer (Fig. 4) .
Notably, we find that 1,25 D 3 is effective for inhibiting the formation of PIN in Nkx3.1; Pten mutant mice, whereas it does not have any apparent affects on the prostatic epithelium of wild-type mice. The implication is that vitamin D may be administered without adverse consequences to a wide spectrum of the population for prevention of prostate cancer. Whereas the levels of 1,25 D 3 used in this study are relatively high and may ultimately lead to hypercalcemia, derivatives of vitamin D (34) or modified schedules of its administration may be effective without the consequences of hypercalcemia. Indeed, it has been shown that intermittent doses of high-level calcitriol reduce the risk of hypercalcemia in humans (35) .
Our findings leave open the question about whether 1,25 D 3 prevents the occurrence of PIN in the Nkx3.1; Pten mutant mice or simply delays it. We favor the latter interpretation because the low-grade PIN lesions that do occur in the 1,25 D 3 -treated mutant mice are virtually identical to those seen in young (<6 months) Nkx3.1; Pten mutant mice. Nonetheless, considering the characteristic age-dependent slow onset of prostate cancer in humans, a significant delay in the occurrence of PIN may still have significant benefits for cancer prevention.
Finally, these data support the further use of the Nkx3.1; Pten mutant mice to design and optimize therapeutic clinical trials in patients at risk for prostate cancer, with PIN, and/or with prostate cancer. The clinical behavior of prostate cancer and the outcome of any clinical trial depend greatly on the point of progression in which patients present as well as any therapy, such as androgen ablation, which may have been instituted; analysis of chemopreventive agents in the context of these conditions makes clinical trial design difficult. Indeed, one important conclusion of our study is that the timing of the delivery of 1,25 D 3 relative to cancer initiation may determine its effectiveness for chemoprevention (Fig. 4) because we have observed that 1,25 D 3 is maximally effective when delivered before, rather than subsequent to, the occurrence of PIN or invasive cancer. Furthermore, our findings suggest that the consequences of vitamin D and its effects on vitamin D receptor and/or androgen receptor signaling may be different in patients with androgen-dependent disease versus those with androgenindependent disease. Considering that most clinical trials done to investigate the efficacy of vitamin D for prostate cancer have been conducted with patients with advanced disease (18) , our findings support the assessment of vitamin D analogues in clinical trials of patients diagnosed with PIN or before the development of PIN. These data also provide insights on tumor marker assessments that can be used in clinical trials to determine the biological effects of these agents.
